Real-world efficacy and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer ...

Shanghai Maxinovel Pharmaceuticals Co. Ltd. has prepared new drug conjugates consisting of small-molecule drugs bonded to radiolabeled chelating agents through linkers acting as programmed cell death ...

HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization ...